Shell Companies
Compare Stocks
4 / 10Stock Comparison
ANSC vs ORGN vs BIOX vs TPVG
Revenue, margins, valuation, and 5-year total return — side by side.
Chemicals
Agricultural Inputs
Asset Management
ANSC vs ORGN vs BIOX vs TPVG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Shell Companies | Chemicals | Agricultural Inputs | Asset Management |
| Market Cap | $373M | $204M | $30M | $234M |
| Revenue (TTM) | $0.00 | $25M | $318M | $97M |
| Net Income (TTM) | $9M | $-69M | $-53M | $-12M |
| Gross Margin | — | 1.8% | 39.1% | 83.5% |
| Operating Margin | — | -321.3% | 0.2% | 77.9% |
| Forward P/E | 59.7x | — | — | 6.2x |
| Total Debt | $838K | $10M | $277M | $469M |
| Cash & Equiv. | $0.00 | $56M | $33M | $20M |
ANSC vs ORGN vs BIOX vs TPVG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jan 24 | May 26 | Return |
|---|---|---|---|
| Agriculture & Natur… (ANSC) | 100 | 111.8 | +11.8% |
| Origin Materials, I… (ORGN) | 100 | 7.7 | -92.3% |
| Bioceres Crop Solut… (BIOX) | 100 | 3.5 | -96.5% |
| TriplePoint Venture… (TPVG) | 100 | 51.5 | -48.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ANSC vs ORGN vs BIOX vs TPVG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ANSC is the #2 pick in this set and the best alternative if efficiency is your priority.
- 2.3% ROA vs ORGN's -19.7%, ROIC -2.3% vs -19.6%
ORGN is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.72, Low D/E 2.9%, current ratio 11.09x
- Beta 1.72, current ratio 11.09x
BIOX lags the leaders in this set but could rank higher in a more targeted comparison.
TPVG carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.77, yield 17.8%
- Rev growth 36.6%, EPS growth 48.8%
- 91.2% 10Y total return vs ANSC's 12.6%
- NIM 7.4% vs ANSC's 5.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 36.6% NII/revenue growth vs BIOX's -28.3% | |
| Value | Better valuation composite | |
| Quality / Margins | 50.6% margin vs ORGN's -275.0% | |
| Stability / Safety | Beta 0.77 vs BIOX's 1.89 | |
| Dividends | 17.8% yield; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +7.4% vs ORGN's -93.5% | |
| Efficiency (ROA) | 2.3% ROA vs ORGN's -19.7%, ROIC -2.3% vs -19.6% |
ANSC vs ORGN vs BIOX vs TPVG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
ANSC vs ORGN vs BIOX vs TPVG — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ANSC leads in 3 of 6 categories
TPVG leads 1 • BIOX leads 1 • ORGN leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
TPVG leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BIOX and ANSC operate at a comparable scale, with $318M and $0 in trailing revenue. TPVG is the more profitable business, keeping 50.6% of every revenue dollar as net income compared to ORGN's -2.8%. On growth, BIOX holds the edge at -16.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $25M | $318M | $97M |
| EBITDAEarnings before interest/tax | -$8M | -$70M | $21M | -$22M |
| Net IncomeAfter-tax profit | $9M | -$69M | -$53M | -$12M |
| Free Cash FlowCash after capex | $0 | -$55M | $37M | -$59M |
| Gross MarginGross profit ÷ Revenue | — | +1.8% | +39.1% | +83.5% |
| Operating MarginEBIT ÷ Revenue | — | -3.2% | +0.2% | +77.9% |
| Net MarginNet income ÷ Revenue | — | -2.8% | -16.6% | +50.6% |
| FCF MarginFCF ÷ Revenue | — | -2.2% | +11.5% | -58.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -43.2% | -16.4% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +6.0% | +57.7% | -37.3% | -2.3% |
Valuation Metrics
BIOX leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
At 4.7x trailing earnings, TPVG trades at a 92% valuation discount to ANSC's 59.7x P/E. On an enterprise value basis, TPVG's 9.0x EV/EBITDA is more attractive than BIOX's 20.0x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $373M | $204M | $30M | $234M |
| Enterprise ValueMkt cap + debt − cash | $374M | $157M | $274M | $683M |
| Trailing P/EPrice ÷ TTM EPS | 59.68x | -2.36x | -0.57x | 4.73x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 6.23x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 4.67x |
| EV / EBITDAEnterprise value multiple | — | — | 19.99x | 9.02x |
| Price / SalesMarket cap ÷ Revenue | — | 6.51x | 0.09x | 2.41x |
| Price / BookPrice ÷ Book value/share | 1.42x | 0.58x | 0.10x | 0.66x |
| Price / FCFMarket cap ÷ FCF | 9999.00x | — | 0.85x | — |
Profitability & Efficiency
ANSC leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ANSC delivers a 2.5% return on equity — every $100 of shareholder capital generates $2 in annual profit, vs $-22 for ORGN. ANSC carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to TPVG's 1.33x. On the Piotroski fundamental quality scale (0–9), ANSC scores 5/9 vs ORGN's 2/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +2.5% | -21.9% | -16.7% | -3.4% |
| ROA (TTM)Return on assets | +2.3% | -19.7% | -6.7% | -1.5% |
| ROICReturn on invested capital | -2.3% | -19.6% | -0.5% | +7.2% |
| ROCEReturn on capital employed | -2.9% | -20.8% | -0.8% | +9.4% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 2 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.00x | 0.03x | 0.94x | 1.33x |
| Net DebtTotal debt minus cash | $838,404 | -$47M | $244M | $449M |
| Cash & Equiv.Liquid assets | $0 | $56M | $33M | $20M |
| Total DebtShort + long-term debt | $838,405 | $10M | $277M | $469M |
| Interest CoverageEBIT ÷ Interest expense | — | -417.10x | -0.07x | -1.02x |
Total Returns (Dividends Reinvested)
ANSC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ANSC five years ago would be worth $11,261 today (with dividends reinvested), compared to $46 for ORGN. Over the past 12 months, TPVG leads with a +7.4% total return vs ORGN's -93.5%. The 3-year compound annual growth rate (CAGR) favors ANSC at 4.0% vs ORGN's -77.9% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +1.3% | -80.6% | -65.2% | -9.6% |
| 1-Year ReturnPast 12 months | +5.6% | -93.5% | -89.5% | +7.4% |
| 3-Year ReturnCumulative with dividends | +12.6% | -98.9% | -95.3% | -5.6% |
| 5-Year ReturnCumulative with dividends | +12.6% | -99.5% | -96.9% | -15.2% |
| 10-Year ReturnCumulative with dividends | +12.6% | -99.5% | -95.1% | +91.2% |
| CAGR (3Y)Annualised 3-year return | +4.0% | -77.9% | -64.0% | -1.9% |
Risk & Volatility
ANSC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ANSC is the less volatile stock with a -0.01 beta — it tends to amplify market swings less than BIOX's 1.89 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ANSC currently trades 99.9% from its 52-week high vs ORGN's 4.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.01x | 1.72x | 1.89x | 0.77x |
| 52-Week HighHighest price in past year | $11.35 | $28.49 | $5.18 | $7.53 |
| 52-Week LowLowest price in past year | $10.70 | $0.20 | $0.35 | $4.48 |
| % of 52W HighCurrent price vs 52-week peak | +99.9% | +4.8% | +9.1% | +76.6% |
| RSI (14)Momentum oscillator 0–100 | 62.1 | 30.0 | 43.5 | 67.6 |
| Avg Volume (50D)Average daily shares traded | 22K | 162K | 799K | 501K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ORGN as "Buy", TPVG as "Hold". Consensus price targets imply 6469.3% upside for ORGN (target: $90) vs 55.1% for TPVG (target: $9). TPVG is the only dividend payer here at 17.76% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | — | Hold |
| Price TargetConsensus 12-month target | — | $90.00 | — | $8.95 |
| # AnalystsCovering analysts | — | 6 | — | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +17.8% |
| Dividend StreakConsecutive years of raises | — | — | — | 0 |
| Dividend / ShareAnnual DPS | — | — | — | $1.02 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +3.1% | 0.0% |
ANSC leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). TPVG leads in 1 (Income & Cash Flow).
ANSC vs ORGN vs BIOX vs TPVG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ANSC or ORGN or BIOX or TPVG a better buy right now?
For growth investors, TriplePoint Venture Growth BDC Corp.
(TPVG) is the stronger pick with 36. 6% revenue growth year-over-year, versus -28. 3% for Bioceres Crop Solutions Corp. (BIOX). TriplePoint Venture Growth BDC Corp. (TPVG) offers the better valuation at 4. 7x trailing P/E (6. 2x forward), making it the more compelling value choice. Analysts rate Origin Materials, Inc. (ORGN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ANSC or ORGN or BIOX or TPVG?
On trailing P/E, TriplePoint Venture Growth BDC Corp.
(TPVG) is the cheapest at 4. 7x versus Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares at 59. 7x.
03Which is the better long-term investment — ANSC or ORGN or BIOX or TPVG?
Over the past 5 years, Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares (ANSC) delivered a total return of +12.
6%, compared to -99. 5% for Origin Materials, Inc. (ORGN). Over 10 years, the gap is even starker: TPVG returned +91. 2% versus ORGN's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ANSC or ORGN or BIOX or TPVG?
By beta (market sensitivity over 5 years), Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares (ANSC) is the lower-risk stock at -0.
01β versus Bioceres Crop Solutions Corp. 's 1. 89β — meaning BIOX is approximately -22656% more volatile than ANSC relative to the S&P 500. On balance sheet safety, Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares (ANSC) carries a lower debt/equity ratio of 0% versus 133% for TriplePoint Venture Growth BDC Corp. — giving it more financial flexibility in a downturn.
05Which is growing faster — ANSC or ORGN or BIOX or TPVG?
By revenue growth (latest reported year), TriplePoint Venture Growth BDC Corp.
(TPVG) is pulling ahead at 36. 6% versus -28. 3% for Bioceres Crop Solutions Corp. (BIOX). On earnings-per-share growth, the picture is similar: Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares grew EPS 72. 7% year-over-year, compared to -1704. 7% for Bioceres Crop Solutions Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ANSC or ORGN or BIOX or TPVG?
TriplePoint Venture Growth BDC Corp.
(TPVG) is the more profitable company, earning 50. 6% net margin versus -267. 6% for Origin Materials, Inc. — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -271. 3% for ORGN. At the gross margin level — before operating expenses — TPVG leads at 83. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ANSC or ORGN or BIOX or TPVG more undervalued right now?
Analyst consensus price targets imply the most upside for ORGN: 6469.
3% to $90. 00.
08Which pays a better dividend — ANSC or ORGN or BIOX or TPVG?
In this comparison, TPVG (17.
8% yield) pays a dividend. ANSC, ORGN, BIOX do not pay a meaningful dividend and should not be held primarily for income.
09Is ANSC or ORGN or BIOX or TPVG better for a retirement portfolio?
For long-horizon retirement investors, Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares (ANSC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
01)). Bioceres Crop Solutions Corp. (BIOX) carries a higher beta of 1. 89 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ANSC: +12. 6%, BIOX: -95. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ANSC and ORGN and BIOX and TPVG?
These companies operate in different sectors (ANSC (Financial Services) and ORGN (Basic Materials) and BIOX (Basic Materials) and TPVG (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ANSC is a small-cap quality compounder stock; ORGN is a small-cap quality compounder stock; BIOX is a small-cap quality compounder stock; TPVG is a small-cap high-growth stock. TPVG pays a dividend while ANSC, ORGN, BIOX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.